Company intelligence / Profile preview

Moexa Pharmaceuticals

West Haven, Connecticut, United Stateslinkedin.com ↗

Ownership: Private
Employees: ~6
Development stage: Preclinical

Overview

Moexa has developed preclinical-stage SMAD3 inhibitors showing promising in vivo results against various cancers with potential applications in fibrosis. Their compounds have demonstrated dose-dependent efficacy in preclinical studies, enhancing NK cell proliferation, reducing tumor angiogenesis, and mitigating matrix degradation without the toxicity typically associated with TGF-β therapies.[7][8]

Therapeutic areas: OncologyPulmonology
Modalities: Small molecules
Industry: Biotech

Partnerships

Receptor.AI (partnership announced February 10, 2025)[7][8]

Beyond the preview

Go deeper on Moexa Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Moexa Pharmaceuticals.

Explore the full profile